Spotlight on General Practice

Credits: 0.50 CME / CNE
Early Diagnosis and Disease Monitoring: Pathology and Biomarkers
Richard Isaacson, MD
AcademicCME

Early Diagnosis and Disease Monitoring: Pathology and Biomarkers

Start

Accredited By

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 CNE Contact Hours
Released: December 7, 2017
Expires: April 5, 2019
30 Minutes to complete

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

  1. Review the pathology of Alzheimer’s disease, including disease monitoring and specific biomarkers for early diagnosis
  2. Identify the assessment and testing strategies for early diagnosis, monitoring, and personalized treatment of AD

Activity Description

In this module of a Four-Part Expert Interview Series, Max Lugavere, along with Dr. Richard S. Isaacson, course chair, will explore non-pharmacological approaches to managing patients with Alzheimer’s disease (AD). Multi-modal intervention factors, including nutrition exercise, sleep hygiene and continued education, among others, will be reviewed, and best practices relayed. The faculty will also highlight recent clinical trial data regarding non-pharmacological methods of AD patient care. Clinical relevance of said data, both now and in the pipeline, will be deliberated. Following this educational activity, learners will have a better grasp of non-pharmacological intervention techniques as well as their potential impact in current and forthcoming AD patient care.

Statement of Educational Need

Health care team members need to understand the pathology of Alzheimer’s disease in order to treat it most effectively, including the biomarkers for early diagnosis.

Agenda

Early Diagnosis and Disease Monitoring: Pathology and Biomarkers

Faculty

Program Chair:
Richard S. Isaacson, MD

Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York


Program Faculty:
James E. Galvin, MD, MPH

Professor and Associate Dean for Clinical Research
Director, Comprehensive Center for Brain Health
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Florida


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.


Faculty
Relationship Identified With:
Richard S. Isaacson, MD
Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
James E. Galvin, MD, MPH
Nothing to disclose.

Non-faculty

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Designation of Credit

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hours.

Instructions for Receiving Credit

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity has been supported by an independent educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

General Practice Presentations

0.75 CME
Postgraduate Institute for Medicine
Global Perspectives in RA: The Role of New Biologics for Optimal Management

Global Perspectives in RA: The Role of New Biologics for Optimal Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: August 30, 2018
Expires: August 29, 2019
45 minutes to complete

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Media

Internet

Target Audience

Clinicians involved in the care of patients with rheumatoid arthritis (RA).

Learning Objectives

  • Describe involvement of the IL-6 signaling pathway in the pathophysiology, extra-articular symptomology, and associated comorbidities of rheumatoid arthritis (RA), and the role of cytokine-targeted therapy in the treatment of RA
  • Incorporate validated and guideline-recommended RA disease activity monitoring to guide appropriate management of patients
  • Use a treat-to-target approach for managing RA that personalizes therapy by cycling or switching treatment options in nonresponsive patients, and takes into account data for new and emerging biologic and targeted synthetic DMARDs
  • Develop individualized RA treatment strategies that incorporate patient preferences, shared decision making, and patient education

 

Faculty

Paul Emery, MA, MD, FRCP, FMedSci (Chair)
Arthritis Research UK Professor of Rheumatology
Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds
Director, Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds, England (UK)


Jonathan Kay, MD
Professor of Medicine
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Director of Clinical Research, Division of Rheumatology
University of Massachusetts Medical School
Worcester, Massachusetts (USA)


Josef S. Smolen, MD
Professor of Medicine
Chairman, Division of Medicine and Department of Medicine 3
Medical University of Vienna
Vienna, Austria (Europe)


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Paul Emery, MA, MD, FRCP, FMedSci, has affiliations with AbbVie, BMS, MSD, Pfizer, and Roche (Contracted Research/Grants); AbbVie, BMS, MSD, Novartis, Pfizer, Roche, and UCB (Consulting Fees); and AbbVie, BMS, MSD, Novartis, Roche, and UCB (Speakers' Bureau).
  • Jonathan Kay, MD, has affiliations with Eli Lilly and Company, Gilead, Pfizer, and UCB (Contracted Research/Grants); and Amgen, Boehringer Ingelhelm GmbH, Celgene, Celltrion Healthcare, Janssen, Merck Sharpe & Dohme, Myriad Genetics, Pfizer, Roche, Samsung Bioepis, and Sandoz (Consulting Fees). 
  • Josef S. Smolen, MD, has affiliations with AbbVie, Astra-Zeneca, Eli Lilly and Company, Janssen, MSD, Pfizer, and Roche (Contracted Research/Grants); and AbbVie, Amgen, Astra-Zeneca, Astro, BMS, Celgene, Celltrion, Chugai, Gilead, Glaxo, Eli Lilly and Company, ILTOO, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, and UCB (Consulting Fees).

Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

YOUR FEEDBACK IS IMPORTANT!

Complete the Evaluation form for this activity and be entered into a drawing for a $100* Amazon Gift card.
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

The activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
Integrity Continuing Education, Inc.
Optimizing the Care of Patients with Severe Asthma through Personalized Disease Management

Optimizing the Care of Patients with Severe Asthma through Personalized Disease Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: June 25, 2018
Expires: June 25, 2019
45 minutes to complete

Provided By


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and internal medicine physicians involved in the care of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify known phenotypes and endotypes that can inform the development of personalized treatment plans for patients with severe asthma
  • Describe clinical trial data on the efficacy and safety of new and emerging therapies for the treatment of severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this educational activity will provide clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

J. Mark FitzGerald, MD
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia


Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, Colorado


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

J. Mark FitzGerald, MD
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Merck, Novartis Pharmaceuticals Corporation, TEVA
Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Merck, Novartis Pharmaceuticals Corporation, TEVA
Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi

Michael E. Wechsler, MD, MMSc
Consulting Fees: Amgen, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi/Regeneron, TEVA
Contracted Research: AstraZeneca Pharmaceuticals LP, Sanofi/Regeneron, TEVA

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 25, 2018 through June 25, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 80% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca Pharmaceuticals LP do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

1.00 CME / CNE
American Heart Association
CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV

CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV

Start

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: June 28, 2017
Expires: June 28, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) State the CDC/USPSTF recommendation for universal opt-out HIV testing 2) Discuss preventive approaches to reduce risk of ASCVD in patients infected with HIV 3) Recognize the challenge of predicting cardiovascular risk in patients who are HIV-positive 4) Examine the treatment of ASCVD in patients who are HIV-positive

Activity Description

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Additionally, the program reviews epidemiologic patterns in HIV and the relevance of these for understanding the scope of CVD among HIV-infected individuals. Important concepts related to HIV screening and prevention, as well as CVD screening and prevention will be discussed; including new developments and existing barriers regarding CVD treatment for HIV-infected individuals will be reviewed. The activity uses a case-based format interspersed with didactic training to bridge the gap between theory and practice for practitioners caring for HIV-infected individuals.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - Presentation of Case Studies: Reducing Cardiovascular Risk in Patients with HIV

15 minutes – Q & A

Presenters

Matthew J. Feinstein, MD
Assistant Professor of Medicine (Cardiology) and Preventive Medicine
Northwestern Medicine
Feinberg School of Medicine
Chicago, IL


David G. Weismiller, MD, ScM, FAAFP
Professor of Family Medicine
University of Nevada, Las Vegas
School of Medicine,
Las Vegas, NV


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 06/28/2017

TERMINATION DATE: 06/28/2020

LAST REVIEW DATE: June 2017

JOINT ACCREDITATION TERM: 06/28/2017 – 06/28/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/28/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.50 CME
Postgraduate Institute for Medicine
Early and Aggressive Approaches to RA Management to Minimize Disease Progression and Improve Quality of Life

Early and Aggressive Approaches to RA Management to Minimize Disease Progression and Improve Quality of Life

Start

Activity Details

Free CME
1.5 AMA PRA Category 1 Credits
Released: May 1, 2018
Expires: June 17, 2019
1.5 hours to complete

Faculty

Iain B. McInnes, PhD, FRCP, FRSE, FMedSci
Iain B. McInnes, PhD, FRCP, FRSE, FMedSci
Muirhead Chair of Medicine
Director of the Institute of Infection, Immunity, and Inflammation
University of Glasgow
Glasgow, Scotland


Marc D. Cohen, MD
Marc D. Cohen, MD
Emeritus Professor of Medicine, Mayo Clinic
Rochester, Minnesota
Adjunct Professor of Medicine
Division of Rheumatology, National Jewish Health
Denver, Colorado


Jeffrey R. Curtis, MD
Jeffrey R. Curtis, MD
Professor of Medicine
The William J. Koopman Endowed Professor
in Rheumatology and Immunology
Director, Arthritis Clinical Intervention Program
University of Alabama at Birmingham
Birmingham, Alabama


Jointly provided by

Commercial Support Statement

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Method of Participation

Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via email or you may print it out at that time.

Inquiries may be directed to Global Academy for Medical Education at info@globalacademycme.com or (973) 290-8225 or the Postgraduate Institute for Medicine at (720) 895-5357.

Joint Accreditation Statement

Accreditation Council for Pharmacy Education In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This enduring activity is intended for rheumatologists, internal medicine physicians with a secondary specialty in rheumatology, physician assistants, and other clinicians who treat patients with rheumatic diseases.

Educational Needs

Clinical studies on patients with rheumatoid arthritis have consistently found that patients are more likely to respond and more likely to reach remission if they are treated with disease-modifying antirheumatic drugs (DMARDs) within 3 to 6 months of symptom onset. But studies of patients in clinical practice find that diagnosis is often delayed, and typically treatment begins a year or more after symptom onset. Clinicians need information on strategies to enable earlier treatment. Guidelines also recommend a treat-to-target approach with a goal of sustained remission. This approach requires ongoing monitoring and treatment changes to meet patient needs. New medications have been approved recently, adding to the rheumatologist’s armamentarium for treating rheumatoid arthritis.

Learning Objectives

At the conclusion of this program, participants should be better able to:

  • Design appropriate strategies to increase the timeliness of rheumatoid arthritis diagnosis and subsequent linkage to evidence-based care
  • Design appropriate strategies to relieve articular and systemic symptoms of rheumatoid arthritis
  • Design strategies for using the most appropriate therapies based on the safety and efficacy data of the emerging classes of therapies for rheumatoid arthritis, including anti-interleukin (IL)-6/IL-6R agents, tumor necrosis factor (TNF) inhibitors, and other biologic disease-modifying antirheumatic drugs (DMARDs)
  • Design treatment strategies for rheumatoid arthritis that take into consideration recommendations from current guidelines and emerging data from clinical trials
  • Describe the data presented at national and global scientific conferences that may help clinicians achieve the treatment goals for rheumatoid arthritis

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Marc D. Cohen, MD, has nothing to disclose.

Jeffrey R. Curtis, MD, Consultant: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Crescendo Bioscience, Ortho-McNeil-Janssen Pharmaceuticals, Pfizer, and UCB. Grant/Research Support: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Crescendo Bioscience, Ortho-McNeil-Janssen Pharmaceuticals, Roche/Genentech, Pfizer, and UCB.

Iain B. McInnes, PhD, FRCP, FRSE, FMedSci, Consultant: AbbVie, Galapagos, Lilly, and Pfizer. Grant/Research Support: Bristol-Myers Squibb, Janssen, Pfizer, and UCB.

The planning staff and content managers hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Global Academy for Medical Education Staff: Mike LoPresti; Shirley V. Jones, MBA; and Margaret McLauglin, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Postgraduate Institute for Medicine: planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1.00 CME / CNE
Postgraduate Institute for Medicine
Clinical Conversations™: Achieving Success in RA Assessment and Management

Clinical Conversations™: Achieving Success in RA Assessment and Management

Start

Jointly Provided By

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 ANCC contact hour
0.5 APRN contact hour
Released: February 27, 2018
Expires: February 27, 2019
1 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of clinicians who manage patients with rheumatoid arthritis (RA).

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of RA and provide a rationale for anti-cytokine therapy as a treatment approach
  2. Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with RA
  3. Develop individualized treatment plans for patients with rheumatoid arthritis that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (dMARDs) based on safety and efficacy data
  4. Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options
  5. Integrate shared decision making and other patient education strategies for patients with RA

Activity Description

This exciting interactive activity in RA features 2 patient cases, challenging questions related to the cases, and video vignettes of the real patients presented during the activity. You will have an opportunity to hear from our expert faculty and learn from the patients' perspectives. Effective management of RA requires appropriate treatment selection up front, regular disease activity monitoring, and patient engagement. New and novel treatment approaches will also be discussed.

Faculty

Martin Jan Bergman, MD, FACR, FACP, FCPP
Clinical Associate Professor of Medicine
Drexel University School of Medicine
Philadelphia, PA
Chief, Division of Rheumatology
Taylor Hospital
Ridley Park, PA


Sergio Schwartzman, MD
Franchellie M. Cadwell Associate Professor of Clinical Medicine
Weill Cornell Medical College
Associate Attending Physician
New York Presbyterian Hospital
Hospital for Special Surgery
New York, NY


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Martin Jan Bergman, MD, FACR, FACP, FCPP, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Sanofi (Advisory Boards); AbbVie, Celgene, Novartis, Pfizer, and Sanofi (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents); and Johnson & Johnson, Merck, and Pfizer (Ownership Interest).

  • Sergio Schwartzman, MD, has affiliations with AbbVie, Crescendo, Genentech, Hospira, Janssen, Novartis, Pfizer, Regeneron, Sanofi, and UCB (Speaker’s Bureau); Amgen, Gilead, Medtronic, and Pfizer (Ownership Interest); AbbVie, Crescendo, Epirus, Genentech, Hospira, Janssen, Lilly, Novartis, Pfizer, Regeneron, and Sanofi (Consulting Fees); and Crescendo (Advisory Board).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Lobna M. Eldasher, PharmD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1 AMA PRA Category 1 Credit(s)™, 1.0 ANCC contact hour, and 0.5 APRN contact hour. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

0.50 CME
Postgraduate Institute for Medicine
Effective Practice Strategies to Achieve Earlier RA Diagnosis and Faster Initiation of Care

Effective Practice Strategies to Achieve Earlier RA Diagnosis and Faster Initiation of Care

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: December 28, 2017
Expires: December 27, 2018

Jointly provided by

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Design appropriate evidence-based strategies for increasing the timeliness both of the diagnosis of rheumatoid arthritis and the initiation of treatment

Faculty

Iain B. McInnes, FRCP, PhD, FRSE, FMedSci
Muirhead Chair of Medicine
Director of the Institute of Infection, Immunity, and Inflammation
University of Glasgow
Glasgow, Scotland

Marc D. Cohen, MD
Emeritus Professor of Medicine
Mayo Clinic
Rochester, Minnesota
Adjunct Professor of Medicine
Division of Rheumatology
National Jewish Health
Denver, Colorado

Jeffrey R. Curtis, MD
Professor of Medicine
The William J. Koopman Endowed Professor in Rheumatology and Immunology
Director, Arthritis Clinical Intervention Program
University of Alabama, Birmingham

Program Overview

Delays in diagnoses and early intervention of rheumatic and musculoskeletal diseases, including rheumatoid arthritis (RA), can cause unnecessary disease progression, reduce chances of remission, decrease patients' quality of life, increase co-morbidities, reduce life expectancy, and increase the added cost burden on global healthcare systems. A growing body of evidence supports the concept of a window of opportunity (3 to 6 months after onset of symptoms) during which initiating treatment for RA can relieve symptoms, minimize comorbidities, and reduce the risk for progression and long-term disability. Global medical society guidelines have been revised recently to underscore the importance of earlier diagnosis of RA and to encourage the earlier use of disease modifying antirheumatic drugs (DMARDs) involving a treat-to-target strategy. Clinicians need education about these developments, about the use of established and emerging therapeutic agents for RA, and about strategies for preparing their practices to better manage patients earlier in the course of rheumatic disease.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Global Academy of Medical Education. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on December 28, 2017 and is valid for one year. Requests for credit must be made no later than December 27, 2018.

Instructions for Obtaining Credit

In order to receive credit, participants must complete the online evaluation and post-test at the end of this program. Participants must also score at least a 70% on the post-test. Statements of credit will be issued upon completion of the evaluation and post-test.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure Declarations

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Marc Cohen, MD
Has nothing to disclose.

Iain B. McInnes, FRCP, PhD, FRSE, FMedSci
Consultant: AbbVie; Galapagos Pharma; Lilly; Pfizer.
Grant/Research Support: Bristol- Myers Squibb; Janssen; Pfizer; UCB.

Jeffrey Curtis, MD
Consultant: AbbVie, Amgen, Bristol- Myers Squibb, Crescendo Bioscience, Inc, CORRONA, Ortho-McNeil- Janssen Pharmaceutical Company, Pfizer Inc., and UCB.
Grant/Research Support: AbbVie Inc, Amgen, Inc, Bristol-Myers Squibb, Crescendo Bioscience, Inc, CORRONA, Ortho-McNeil- Janssen Pharmaceutical Company, Roche/Genentech, Pfizer Inc., and UCB.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Mike LoPresti
Nothing to disclose

Margaret McLaughlin, PhD
Nothing to disclose

Ron Schaumburg
Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support Statement

This activity is supported by an educational grant from Sanofi-Regeneron.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Copyright © 2018 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc., and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, and Postgraduate Institute for Medicine will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

0.50 CME
Postgraduate Institute for Medicine
The Impact of Earlier Diagnosis and Timelier Treatment of Rheumatoid Arthritis on Patient Outcomes and Healthcare Systems

The Impact of Earlier Diagnosis and Timelier Treatment of Rheumatoid Arthritis on Patient Outcomes and Healthcare Systems

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: December 28, 2017
Expires: December 27, 2018

Jointly provided by


Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Apply the research that defined the benefits associated with early diagnosis and treatment of RA

Faculty

Marc D. Cohen, MD
Emeritus Professor of Medicine
Mayo Clinic
Rochester, Minnesota
Adjunct Professor of Medicine
Division of Rheumatology
National Jewish Health
Denver, Colorado

Iain B. McInnes, FRCP, PhD, FRSE, FMedSci
Muirhead Chair of Medicine
Director of the Institute of Infection, Immunity, and Inflammation
University of Glasgow
Glasgow, Scotland

Program Overview

Delays in diagnoses and early intervention of rheumatic and musculoskeletal diseases, including rheumatoid arthritis (RA), can cause unnecessary disease progression, reduce chances of remission, decrease patients' quality of life, increase co-morbidities, reduce life expectancy, and increase the added cost burden on global healthcare systems. A growing body of evidence supports the concept of a window of opportunity (3 to 6 months after onset of symptoms) during which initiating treatment for RA can relieve symptoms, minimize comorbidities, and reduce the risk for progression and long-term disability. Global medical society guidelines have been revised recently to underscore the importance of earlier diagnosis of RA and to encourage the earlier use of disease modifying antirheumatic drugs (DMARDs) involving a treat-to-target strategy. Clinicians need education about these developments, about the use of established and emerging therapeutic agents for RA, and about strategies for preparing their practices to better manage patients earlier in the course of rheumatic disease.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Global Academy of Medical Education. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on December 28, 2017 and is valid for one year. Requests for credit must be made no later than December 27, 2018.

Instructions for Obtaining Credit

In order to receive credit, participants must complete the online evaluation and post-test at the end of this program. Participants must also score at least a 70% on the post-test. Statements of credit will be issued upon completion of the evaluation and post-test.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure Declarations

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Marc Cohen, MD
Has nothing to disclose.

Iain B. McInnes, FRCP, PhD, FRSE, FMedSci
Consultant: AbbVie; Galapagos Pharma; Lilly; Pfizer.
Grant/Research Support: Bristol- Myers Squibb; Janssen; Pfizer; UCB.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Mike LoPresti
Nothing to disclose

Margaret McLaughlin, PhD
Nothing to disclose

Ron Schaumburg
Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support Statement

This activity is supported by an educational grant from Sanofi-Regeneron.

Course Viewing Requirements

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:

Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Copyright © 2018 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc., and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, and Postgraduate Institute for Medicine will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

1.00 CME
University of California, San Diego School of Medicine
Issues and Updates in Hereditary Angioedema

Issues and Updates in Hereditary Angioedema

Start

Jointly Provided By

University of California, San Diego School of Medicine and RMEI Medical Education, LLC.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: December 27, 2017
Expires: December 27, 2018
1.0 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of allergy/immunology physicians, allergy/immunology NPs and PAs, dermatology physicians, dermatology NPs and PAs.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Recognize the possibility of hereditary angioedema (HAE) in patients who present with angioedema and integrate a diagnostic workup for angioedema that includes analysis for the various types of HAE (Type I, Type II, and normal C1-INH)
  2. Incorporate current, novel, and emerging treatments for HAE based on an understanding of their efficacy, safety, and guidance for use

Activity Description

This interactive multi-challenge activity addresses issues and updates in HAE. Based on the proceedings from a live continuing medical education series, it contains slides, expert audio, and commentary on some of the most current and important topics in HAE. Patient case challenges allow you to test your knowledge and skill in diagnosing and treating this important disease. Commentary from faculty experts will increase your understanding of the newest developments in HAE.

Statement of Educational Need

The treatment of hereditary angioedema (HAE) is rapidly evolving. After many years of limited treatment options, several effective medications for HAE have been introduced into clinical practice over the past 8 years. Now, a second wave of novel therapies are poised to reach the clinic. While the impact of these treatments is not yet known, it is likely the HAE treatment paradigm will shift yet again given the broadening therapeutic options available to physicians and patients.

Faculty

Marc A. Riedl, MD, MS
Professor of Medicine 
Clinical Director, US HAEA Angioedema Center 
Division of Rheumatology, Allergy and Immunology 
University of California, San Diego 
San Diego, CA


Michael E. Manning, MD, FAAAAI, FACAAI
President/Medical Director 
Medical Research of Arizona 
Allergy, Asthma & Immunology Associates, Ltd. 
Scottsdale, AZ


Daniel F. Soteres, MD, MPH
Physician Partner
Asthma & Allergy Associates and Research Center
Colorado Springs, CO


Disclosure of Conflicts of Interest

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity, and scientific rigor. All persons involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms: 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Marc A. Riedl, MD, MS, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Ionis, Pharming, Shire (Research); Adverum, Alnylam, BioCryst, CSL Behring, KalVista, Pharming, Shire (Consulting Fees)
  • Michael E. Manning, MD, FAAAAI, FACAAI, has affiliations with CSL Behring, Dyax, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Dyax, Pharming, Shire (Research); CSL Behring, Pharming, Shire (Advisory Board); CSL Behring (Consulting Fees)
  • Daniel F. Soteres, MD, MPH, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); CSL Behring, Shire (Research); CSL Behring, Shire (Advisory Board); CSL Behring, Pharming, Shire (Consulting Fees)

The CME staff, meeting planners, and CME committee reviewers do not have any relevant financial relationships to disclose.

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, San Diego School of Medicine and RMEI Medical Education, LLC. The University of California, San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The University of California, San Diego School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural Competency
This activity is in compliance with California Assembly Bill 1195 which requires CME courses with patient care components to include curriculum in the subjects of cultural and linguistic competencies. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables healthcare professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. Cultural and Linguistic Competency was incorporated into the planning of this activity. Additional resources on cultural and linguistic competency and information about AB1195 can be found on the UC San Diego CME website at http://cme.ucsd.edu.

How to Receive Credit

The estimated time to complete this activity is 1 hour. To obtain credit, participants should view the presentation, answer the multiple-choice post-test questions, and complete the evaluation form online to receive a certificate.

Physicians/DOs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

The activity is supported in part by educational grants from CSL Behring, Pharming Healthcare, Inc., and Shire.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

1.00 CME / CNE
Postgraduate Institute for Medicine
Clinical Convergence®: Achieving Success in RA Assessment and Management

Clinical Convergence®: Achieving Success in RA Assessment and Management

Start

Jointly Provided By

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 ANCC contact hour
0.5 APRN contact hour
Released: December 26, 2017
Expires: December 26, 2018
1 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of clinicians who manage patients with rheumatoid arthritis (RA).

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of rheumatoid arthritis (RA) and provide a rationale for anti-cytokine therapy as a treatment approach
  2. Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with RA
  3. Develop individualized treatment plans for patients with RA that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (dMARDs) based on safety and efficacy data
  4. Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options
  5. Integrate shared decision making and other patient education strategies for patients with RA

Activity Description

This exciting interactive activity in rheumatoid arthritis (RA) features 2 patient cases, challenging questions related to the cases, and video vignettes of the real patients presented during the activity. You will have an opportunity to hear from our expert faculty and learn from the patients' perspectives. Effective management of RA requires appropriate treatment selection up front, regular disease activity monitoring, and patient engagement. New and novel treatment approaches will also be discussed.

Faculty

Martin Jan Bergman, MD, FACR, FACP, FCPP
Clinical Associate Professor of Medicine
Drexel University School of Medicine
Philadelphia, PA
Chief, Division of Rheumatology
Taylor Hospital
Ridley Park, PA


Sergio Schwartzman, MD
Franchellie M. Cadwell Associate Professor of Clinical Medicine
Weill Cornell Medical College
Associate Attending Physician
New York Presbyterian Hospital
Hospital for Special Surgery
New York, NY


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Martin Jan Bergman, MD, FACR, FACP, FCPP, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Sanofi (Advisory Boards); AbbVie, Celgene, Novartis, and Sanofi (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents); and Johnson & Johnson, Merck, and Pfizer (Ownership Interest).
  • Sergio Schwartzman, MD, has affiliations with AbbVie, Crescendo, Genentech, Hospira, Janssen, Novartis, Pfizer, Regeneron, Sanofi, and UCB (Speaker’s Bureau); Amgen, Gilead, Medtronic, and Pfizer (Ownership Interest); AbbVie, Crescendo, Epirus, Genentech, Hospira, Janssen, Lilly, Novartis, Pfizer, Regeneron, and Sanofi (Consulting Fees); and Crescendo (Advisory Board).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.0 contact hour is provided by the Postgraduate Institute for Medicine. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™, 1.0 ANCC contact hour, and 0.5 APRN contact hour. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi, Genzyme, and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

0.50 CME
Postgraduate Institute for Medicine
First Know Thyself: Improving Patient Outcomes in Moderate-to-Severe and Difficult to Treat Pediatric Asthma

First Know Thyself: Improving Patient Outcomes in Moderate-to-Severe and Difficult to Treat Pediatric Asthma

Start

Jointly Provided By

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: December 12, 2017
Expires: December 12, 2018
30 minutes to complete

Target Audience

Allergy/Immunology and pulmonology clinicians who manage pediatric patients with asthma.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Optimally utilize recommended therapy algorithms and therapies for asthma in children 6 to 11 years of age based on new data and guidelines
  2. Better define optimal asthma control in childhood in order to implement asthma control
  3. Implement newer and more effective treatment for children with resistant or moderate-to-severe and severe asthma based on efficacy and safety data and different asthma endotypes
  4. Employ a strong patient-provider collaborative approach to managing pediatric patients with asthma that includes patient and caregiver education, engagement, and shared decision making

Faculty

Bradley E. Chipps, MD
Medical Director, Respiratory Therapy and the Cystic Fibrosis Center
Sutter Medical Center
Capital Allergy and Respiratory Disease Center
Sacramento, CA


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Bradley E. Chipps, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, and TEVA (Consulting Fees).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Leslie Sharp has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an educational grant from Genentech.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Pages